Breaking News
April 25, 2018 - Studies provide advanced knowledge about renal cancer
April 25, 2018 - Researchers develop low-cost, portable laboratory on a phone to detect infections
April 25, 2018 - Early treatment improves leg ulcer healing rates
April 25, 2018 - U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib to Treat Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
April 25, 2018 - Redefined Alzheimer’s biology has implications for drug design
April 25, 2018 - BetterYou’s Iron Oral Spray recognized as ‘Best New Health and Nutrition Product’
April 24, 2018 - New imaging technology to effectively screen for colorectal cancer among young adults
April 24, 2018 - UW developmental psychologist wins 2018 Alan T. Waterman Award
April 24, 2018 - Adipose-derived mesenchymal stem cells combined with fibrin matrix influences restoration of motor functions
April 24, 2018 - Exposure to toxin found in sheep may be linked to development of MS
April 24, 2018 - FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-Induced Nausea and Vomiting
April 24, 2018 - Is Alzheimer’s caused by disruptions to the brain’s energy supply?
April 24, 2018 - Low concentrations of antibiotics can develop high antibiotic resistance in bacteria
April 24, 2018 - Imagined and real movements have similar brain mechanisms, research suggests
April 24, 2018 - Alcoholic drinks affect oral bacteria tied to diseases
April 24, 2018 - Mechanism in Non-Contact ACL Tears Similar in Men, Women
April 24, 2018 - Buprenorphine may be safer than methadone if treatment duration is longer, study suggests
April 24, 2018 - NF-κB1 gene known to drive cancer development is critical for preventing stomach cancers
April 24, 2018 - New tool helps blind, low-vision users navigate modern webpages more easily
April 24, 2018 - Hippo pathway plays essential role in embryonic development of the mouse heart
April 24, 2018 - Vegetarian diet and Mediterranean diet close to each other in health benefits
April 24, 2018 - FSU receives $1.5 million federal grant for innovative suicide prevention research
April 24, 2018 - Health Tip: Screening for Cancer in Older Adults
April 24, 2018 - Investigators highlight potential of exercise in addressing substance abuse in teens
April 24, 2018 - Study shows people might develop dementia later and live with it for a shorter period of time
April 24, 2018 - EMBL scientists develop new illumination method to manage neuropathic pain
April 24, 2018 - New compound could offer pain-relieving properties without risk of addiction
April 24, 2018 - New drug treatment could be promising therapeutic approach for millions with asthma
April 24, 2018 - Study provides guidance on using cannabis for treatment of stress, anxiety, and depression
April 24, 2018 - By Royal approval: Queen’s Award success for Elucigene
April 24, 2018 - The role of ‘extra’ DNA in cancer evolution and therapy resistance
April 24, 2018 - Researchers identify tools that caregivers could use to detect delirium in older adults
April 24, 2018 - What to Look Out For
April 24, 2018 - Drugs prescribed for newborns vary widely between NICUs, study finds
April 24, 2018 - FM4200 pressure-resistant mass flow meter from Sensirion
April 24, 2018 - Study links past experiences with bias and avoidance of doctors in women with higher BMI
April 24, 2018 - Role of extrachromosomal pieces of DNA in cancer development and treatment resistance
April 24, 2018 - Rehabilitation technique for stroke appears beneficial for multiple sclerosis patients
April 24, 2018 - Women who find purpose and meaning in life less likely to have anxiety, study shows
April 24, 2018 - Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
April 24, 2018 - Suicide and homicide rates show large racial disparities across US states
April 24, 2018 - Scientists develop tissue-engineered models to better understand cancer metastases
April 24, 2018 - NuProbe to commercialize Wyss Institute’s new technology to facilitate precision medicine
April 24, 2018 - Special series explores pasteurized donor human milk use for hospitalized infants
April 24, 2018 - Slight changes in patient’s position during radiotherapy may impact survival chances
April 24, 2018 - FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
April 24, 2018 - After knee replacement, play on
April 24, 2018 - Contact precautions do not limit spread of drug-resistant bacteria in ICUs
April 24, 2018 - Researchers discover genetic catalysts that accelerate evolution of antibiotic resistance in bacteria
April 24, 2018 - WPI researcher launches mobile app for assessing perinatal depression in women
April 24, 2018 - Researchers identify superior blood-based biomarker for assessing sports-related concussions
April 24, 2018 - Gene Therapy Found to Be Promising for β-Thalassemia
April 24, 2018 - Bariatric surgery can lead to changes in relationship status
April 24, 2018 - GPs must embrace digital technologies to make healthcare access easier for patients
April 24, 2018 - Novel stem cell therapy may transform current paradigms for treating heart failure patients
April 24, 2018 - Maternal depression during and after pregnancy linked to poorer child neurodevelopment
April 24, 2018 - Vitamin D and magnesium supplements provide right nutritional support to athletes
April 24, 2018 - Could a Tattoo Someday Spot Your Cancer?
April 24, 2018 - Throat reflexes differ in people with tetraplegia and sleep apnea
April 24, 2018 - Study shows no increased risk of breast cancer recurrence after DIEP flap reconstruction
April 24, 2018 - Nearly three-quarters of commonly used medical scopes tainted by bacteria
April 24, 2018 - Home-based treatment program offers robust and sustained relief for IBS patients
April 24, 2018 - New IntelliCyt Cy-Clone PLUS streamlines clone ranking and selection for cell line development
April 24, 2018 - Scientists examine how specific eating patterns could help fight cancer and obesity
April 24, 2018 - Study sheds new light on how bilinguals process language
April 24, 2018 - Probiotics can improve liver health, shows study
April 24, 2018 - Study may explain how chemoresistance evolves over time in some triple-negative breast cancers
April 24, 2018 - Role of midbrain in encoding identity errors
April 23, 2018 - Salamander study provides clues for treating spinal cord injuries
April 23, 2018 - Relaxation after work could give better night’s sleep
April 23, 2018 - Loneliness on its way to becoming Britain’s most lethal condition
April 23, 2018 - Low-cost blood test for multiple myeloma can deliver same diagnostic information as bone biopsy
April 23, 2018 - Metabolic differences may contribute to postpartum weight retention in black moms
April 23, 2018 - Time-Related Deployment Factors Predict Suicide Attempt Risk
April 23, 2018 - Are newborns ugly? Research says newborns rated ‘less cute’ than older babies
April 23, 2018 - Prenatal marijuana use linked to increased chance of low birth weights
April 23, 2018 - Researchers identify target gene in P. aeruginosa infection
April 23, 2018 - New studies related to causes of liver degradation and possible treatments
April 23, 2018 - Studies offer leads for new approaches to treat neurological problems
April 23, 2018 - Promising cell study may offer new opportunities for treating Parkinson’s disease
OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

OCA treatment stabilizes or reverses fibrosis/cirrhosis in patients with primary biliary cholangitis

image_pdfDownload PDFimage_print

The first results from the POISE biopsy sub-study have today confirmed that long-term treatment with obeticholic acid (OCA) leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis (PBC) who have had an incomplete response to ursodeoxycholic acid (UDCA). These results provide the first evidence that improvements in biochemical markers of PBC observed in previous studies are accompanied by anti-fibrotic effects in line with those observed in pre-clinical trials.

‘There is strong evidence from clinical trials that OCA leads to significant reductions in alkaline phosphatase (ALP) that are predicted to improve clinical outcomes of patients with PBC who do not respond adequately to or do not tolerate UDCA’, said Dr Christopher Bowlus from the University of California, Davis in the USA, who presented the results today at The International Liver Congress 2018 in Paris, France. ‘This study offers the first evidence from paired liver biopsies that OCA is indeed a disease-modifying therapy’.

Primary biliary cholangitis is a rare autoimmune liver disease characterized by biliary destruction, progressive cholestasis, and, ultimately, the development of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The primary medical treatment for PBC is UDCA, however, up to 40% of patients have an insufficient response to this treatment, putting them at risk of potentially life-threatening complications.

Obeticholic acid is a potent agonist of the farnesoid X receptor (FXR), which regulates bile acid synthesis and transport. Two previously reported Phase 2 studies and a pivotal Phase 3 study (POISE) confirmed that OCA, primarily in combination with UDCA, leads to significant reductions in serum ALP and improvements in other biochemical liver markers, leading to the recent approval of the treatment by the US Food and Drug Administration (FDA).

The biopsy sub-study of POISE involved patients undergoing liver biopsies prior to, and after 3 years of, treatment with OCA. Biopsies were centrally read and assessed using a six-tier staging system (from no fibrosis to cirrhosis). Thirteen patients – all receiving treatment with UDCA at baseline – had paired biopsies that were adequate for analysis.

At baseline, nine of the 13 patients (69%) presented with pre-cirrhotic fibrosis and four (31%) with cirrhosis. At the last visit before the final biopsy, serum ALP was reduced and direct bilirubin levels were comparable to baseline (median changes from baseline: -99 U/L and 0.0 μmol/L, respectively). After 3 years of OCA treatment, the majority of patients improved (n=6; 46%) or maintained (n=5; 38%) their histological stage, while two patients (15%) deteriorated. Of the four patients with baseline cirrhosis, three (75%) improved to fibrosis without cirrhosis while receiving OCA treatment.

‘Eighty-five percent of the patients with PBC in this study with an incomplete response to UDCA had regression or no worsening of their fibrosis or cirrhosis after 3 years of OCA treatment – a period of time during which we would have expected some degree of fibrosis progression’, said Dr Bowlus. ‘OCA represents the first new treatment approved for PBC in decades, and these results support the potential of OCA to slow disease progression in this group of patients who have the greatest need for new treatments. The results of the ongoing COBALT study will determine if the biochemical improvements of the POISE study and the histological results reported here translate to improved clinical outcomes’ (NCT02308111).

‘Relevant changes are on the way for the management of patients with PBC, for which ursodeoxycholic acid has been the only treatment option for a long time’, said Prof. Marco Marzioni from the University Hospital of Ancona, Italy, and EASL Governing Board Member. ‘Now new medicines are coming and the first of these to be available, obeticholic acid, has been shown to ameliorate surrogate markers of disease progression. The current study, however, reports the first evidence that OCA is also able to halt the deposition of collagen tissue in the liver, a significant outcome for the natural history of PBC’.

Tagged with:

About author

Related Articles